Serum cholesterol and triglycerides in Parkinson`s disease and essential tremor

Borislav Ivanov; Ara Kaprelyan; Ivan Dimitrov; Margarita Grudkova; Natalia Usheva; Vesselina Nestorova; Nadezhda Deleva

doi:10.14748/bmr.v26.1543

Serum cholesterol and triglycerides in Parkinson`s disease and essential tremor

Borislav Ivanov, Ara Kaprelyan, Ivan Dimitrov, Margarita Grudkova, Natalia Usheva, Vesselina Nestorova, Nadezhda Deleva

Abstract

The role of lipid metabolism in the pathogenesis of Parkinson`s disease is still controversial. Most authors suggest that higher The role of lipid metabolism in the pathogenesis of Parkinson`s disease is still controversial. Most authors suggest that higher serum cholesterol may be associated with a lower risk of Parkinson`s disease. Debates exist as to whether essential tremor shares similar neuropathological mechanisms as Parkinson`s disease. We investigated serum total cholesterol and triglyceride levels in a clinical setting of Parkinson`s disease versus essential tremor patients. Two hundred and sixteen Parkinson`s disease patients (126 males), aged 68.04 years, with 4.58 years disease duration and 342 essential tremor patients (118 males), aged 69.39 years, with 5.3 years disease duration were included, hospitalized during a period of 7 years in First Clinic of Neurology, University St Marina Hospital, Varna, Bulgaria. We found insignificantly higher levels of serum total cholesterol and triglyceride in essential tremor patients. Results differ statistically only on gender level with increased cholesterol in males and triglycerides in females. Our findings may indicate divergent pathophysiological mechanisms underlying Parkinson`s disease and essential tremor. Further research may elucidate the role of lipid metabolism changes in both diseases.
Biomed Rev 2015; 26: 43-46.
Key words: serum total cholesterol, triglycerides, Parkinson`s disease, essential tremor

Full Text

References

Liu J, Tang Y, Zhou S, Toh B, McLean C, Li H. Cholesterol involvement in the pathogenesis of neurodegenerative diseases. Mol Cell Neurosci 2010; 43, 1: 33-42. DOI: 10.1016/j.mcn.2009.07.013

Ritz B, Manthripragada A, Qian L, Schernhammer E, Wermuth L, Olsen J, et al.Statin use and Parkinson`s disease in Denmark. Mov Disord 2010; 25, 9: 1210-1216. DOI: 10.1002/mds.23102

Powers K, Smith-Weller T, Franklin G, Longstreth Jr W, Swanson P, Checkoway H. Dietary fats, cholesterol and iron as risk factors for Parkinson`s Disease. Parkinsonism Relat Disord 2009; 15, 1: 47-52. DOI: 10.1016/j. parkreldis.2008.03.002

Roy A, Pahan K. Prospects of statins in Parkinson disease. Neuroscientist 2011; 17: 244-255. DOI: 10.1177/1073858410385006.

Jimenez-Jimenez F, Alonso-Navarro H, GarcÄ±a-MartÄ±n E, Agundez J. The relationship between Parkinson`s disease and essential tremor: Review of clinical, epidemiologic, genetic, neuroimaging and neuropathological data, and data on the presence of cardinal signs of parkinsonism in essential tremor. Tremor Other Hyperk Mov 2012; DOI: http://www.tremorjournal.org/index.php/tremor/ article/view/75

Zhang J, Liu Q. Cholesterol metabolism and homeostasis in the brain. Protein Cell. 2015; 6: 254-264. DOI: 10.1007/s13238-014-0131-3

Ivanova- Smolenskaia I, Korshunova T, Mzhelskaia T. Metabolic disorders in essential tremor. Zh Nevropatol Psikhiatr Im S S Korsakova 1980; 80, 12: 1765-1770.

Huang X, Abbott R, Petrovitch H, Mailman R, Ross G. Low LDL cholesterol and increased risk of Parkinson`s disease: prospective results from Honolulu-Asia Aging study. Mov Disord 2008; 23, 7: 1013- 1018. DOI: 10.1002/mds.22013.

Huang X, Auinger P, Eberly S, Oakes D, Schwarzschild M, Ascherio A, et al. Parkinson Study Group DATATOP Investigators. Serum cholesterol and the progression of Parkinson`s disease: results from DATATOP. PLoS One 2011; 6:e22854. DOI: 10.1371/ journal.pone.0022854

Huang X, Chen H, Miller W, Mailman R, Woodard J, Chen P, et al. Lower low density lipid cholesterol levels are associated with Parkinson`s disease. Mov Disord 2007; 22: 377-381. DOI: 10.1002/mds.21290

Miyake Y, Tanaka K, Fukushima W, Sasaki S, Kiyohara C, Tsuboi Y, et al. Parkinson`s Disease Study Group. Case-control study of risk of Parkinson`s disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan. J Neurol Sci 2010; 293: 82- 86. DOI: 10.1016/j. jns.2010.03.002

Gudala K, Bansal D, Muthyala H. Role of serum cholesterol in Parkinson`s disease: a meta-analysis of evidence. J Parkinsons Dis. 2013; 3, 3: 363-370. DOI: 10.3233/ JPD-130196.

Kelly S, Honglei C, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 2007; 69: 1688-1695. DOI: 10.1212/01.wnl.0000271883.45010.a8

Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J. Total cholesterol and the risk of Parkinson disease. Neurology 2008; 70, 21: 1972- 1979. DOI: 10.1212/01. wnl.0000312511.62699.a8

Undela K, Gudala K, Malla S, Bansal D. Statin use and risk of Parkinson`s disease: a meta-analysis of observational studies. J Neurol 2013; 260, 1: 158- 165. DOI: 10.1007/s00415-012-6606-3

Sääksjärvi K, Knekt P, Männistö S, Lyytinen J, Heliövaara M. Prospective study on the components of metabolic syndrome and the incidence of Parkinson`s disease. Parkinsonism Relat Disord 2015;21:1148-1155. DOI: 10.1016/j.parkreldis.2015.07.017.

de Lau L, Koudstaal P, Hofman A, Breteler M. Serum cholesterol levels and the risk of Parkinson`s Disease. Am J Epidemiol 2006; 164: 998-1002. DOI: 10.1093/aje/ kwj283

Hu G. Total cholesterol and the risk of Parkinson`s disease: A review for some new findings. Parkinsons Dis 2010; 2010:836962. DOI:10.4061/2010/836962

DOI: http://dx.doi.org/10.14748/bmr.v26.1543